NASDAQ: JANXJanux Therapeutics Inc Stock
$11.39-0.07 (-0.61%)
Updated May 26, 2023
JANX Price
$11.39
Fair Value Price
N/A
Market Cap
$476.27M
52 Week Low
$9.40
52 Week High
$23.64
P/E
-7.03x
P/B
1.53x
P/S
55.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.07M
Earnings
-$67.11M
Gross Margin
100%
Operating Margin
-739.81%
Profit Margin
-739.8%
Debt to Equity
0.13
Operating Cash Flow
-$45M
Beta
1.52
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
JANX Overview
Janux Therapeutics Incorporated is a biopharma developing therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients with cancer. Its lead TRACTr product candidates target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company's EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. Janux Therapeutics was incorporated in 2017 and is headquartered in La Jolla, CA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how JANX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JANX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
JANX is good value based on its book value relative to its share price (1.53x), compared to the US Biotechnology industry average (5.18x)
P/B vs Industry Valuation
JANX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more JANX due diligence checks available for Premium users.
Be the first to know about important JANX news, forecast changes, insider trades & much more!
JANX News
Valuation
JANX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.03x
Industry
11.86x
Market
54.23x
JANX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.53x
Industry
5.18x
JANX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JANX's financial health
Profit margin
Revenue
$2.0M
Net Income
-$17.5M
Profit Margin
-852.5%
JANX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
JANX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$353.0M
Liabilities
$41.7M
Debt to equity
0.13
JANX's short-term assets ($321.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JANX's short-term assets ($321.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JANX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.9M
Investing
-$8.7M
Financing
$1.6M
JANX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
JANX vs Biotech Stocks
Janux Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.